熱門資訊> 正文
FibroGen CFO、CMO将于年底前离开公司
2024-09-07 04:52
- FibroGen (NASDAQ:FGEN) said late Friday that its chief financial officer and chief medical officer will both be leaving the company due to budget cuts.
- The company said CFO Juan Graham will stay with the company until Dec. 15, while CMO Dr. Deyaa Adib will leave on Nov. 1. Both were informed of their terminations on Aug. 30, according to an SEC filing.
- FibroGen (FGEN) announced in late July that it was slashing its U.S. workforce by 75% due to disappointing clinical results for its pancreatic cancer drug candidate pamrevlumab.
- Shares of FibroGen (FGEN) closed 8% lower on Friday.
More on FibroGen
- FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript
- FibroGen Q2 2024 Earnings Preview
- FibroGen stock plunges 48% post-market on failed drug studies
- Seeking Alpha’s Quant Rating on FibroGen
- Historical earnings data for FibroGen
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
